Not medical advice. PT-141 is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
PT-141 is listed in our catalogue under “Tanning / Libido.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.
Bremelanotide (PT-141) FDA-approved MC4R agonist for HSDD activates hypothalamic sexual arousal pathways via central melanocortin signaling. t½ 2.7 hours SC.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
These peptides are studied mainly for how they interact with melanocortin receptors and pigmentation biology. That research is separate from human “tanning products” and stays in controlled scientific contexts.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 1.75 mg subcutaneously (FDA-approved dose) · As needed, at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, ≤8 doses per month · SC t½ = 2.7 hr (range 1.9-4.0 hr). Tmax ~1 hr. Vd = 25.0 L. CL = 6.5 L/hr. Protein binding 21%. Excretion: 64.8% urine, 22.8% feces. Most common adverse effect: nausea (40%). Biological effect duration 4-8 hr exceeds plasma half-life. Available as 1.75 mg/0.3 mL autoinjector pen (Vyleesi).
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.
What is PT-141 in plain language?
PT-141 is a research peptide we catalogue under “Tanning / Libido.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.
Does this page give medical advice or dosing instructions for PT-141?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for PT-141?
Use the “View product” button to open the canonical shop listing for PT-141, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for PT-141?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: PT-141, Bremelanotide, Vyleesi, Bremelanotide Acetate, MC4R Agonist, Cyclic MSH Analogue, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH